Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1

The phase 1b NIVIPIT trial shows that in combined therapy with intravenous nivolumab (anti-PD1), intratumoural administration of ipilimumab (anti-CTLA4) offers improved safety and greater efficacy compared with intravenous delivery.

In 61 patients with untreated metastatic melanoma, intratumoural ipilimumab resulted in a 22.6% rate of grade 3–4 adverse events versus 57.1% for intravenous delivery, while maintaining comparable tumour response rates of 68% versus 63%.